Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD40 is a cell-surface receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily. It plays a central role in regulating immune activation and mediating both adaptive and innate immune responses. CD40 is primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, but it can also be found on non-hematopoietic cells including endothelial cells, smooth muscle cells, fibroblasts, epithelial cells, and various tumor types. Upon engagement with its ligand or agonistic antibodies, CD40 triggers intracellular signaling cascades involving TNF receptor-associated factors (TRAFs), leading to the activation of transcription factors such as NFκB.
Agonistic anti-CD40 monoclonal antibodies designed for direct stimulation of the receptor or via FcγR crosslinking mechanisms. Enhance antitumor immunity through improved APC function or direct cytotoxicity.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD40 antigen (CD40).